George R Simon

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi Small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Suite 3170, Tampa, FL 33612, USA
    Chest 123:259S-271S. 2003
  2. ncbi Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
  3. ncbi ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Ste 3170, Tampa FL 33612, USA
    Chest 127:978-83. 2005
  4. ncbi Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    George R Simon
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, MRC 4W, Tampa, FL 33612, USA
    Chest 132:324S-339S. 2007
  5. ncbi Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center Research Institute, Tampa, FL 33612, USA
    Cancer Control 10:388-95. 2003
  6. ncbi Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC 4W, Tampa, FL 33612, USA
    Future Oncol 4:51-9. 2008
  7. ncbi Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
  8. ncbi Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial
    George R Simon
    Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, SRB-2, Tampa, 33612-9416, USA
    Mol Cancer Ther 5:2130-7. 2006
  9. ncbi Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?
    Charu Aggarwal
    Thoracic Oncology Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Compr Canc Netw 8:822-32. 2010
  10. ncbi Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality
    George R Simon
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Int J Biochem Cell Biol 39:1318-28. 2007

Research Grants

  1. Molecular Analysis-Directed Individualised Therapy in Ad
    George Simon; Fiscal Year: 2005

Detail Information

Publications23

  1. ncbi Small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Suite 3170, Tampa, FL 33612, USA
    Chest 123:259S-271S. 2003
    ..Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined...
  2. ncbi Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
    ..In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability...
  3. ncbi ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Ste 3170, Tampa FL 33612, USA
    Chest 127:978-83. 2005
    ..We therefore evaluated the effect of intratumoral ERCC1 expression on survival in non-small cell lung cancer (NSCLC) patients who underwent surgical resection for cure...
  4. ncbi Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    George R Simon
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, MRC 4W, Tampa, FL 33612, USA
    Chest 132:324S-339S. 2007
    ..As part of the guideline, an evidence-based review of the literature was commissioned that enables the reader to assess the evidence as we have attempted to put the clinical implications into perspective...
  5. ncbi Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center Research Institute, Tampa, FL 33612, USA
    Cancer Control 10:388-95. 2003
    ..We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor...
  6. ncbi Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, MRC 4W, Tampa, FL 33612, USA
    Future Oncol 4:51-9. 2008
    ....
  7. ncbi Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
    ..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)...
  8. ncbi Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial
    George R Simon
    Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, SRB-2, Tampa, 33612-9416, USA
    Mol Cancer Ther 5:2130-7. 2006
    ..However, peripheral blood mononuclear cells may not be a predictive biological surrogate for drug-induced modulation of topo levels in tumor tissues and should be further explored in larger studies...
  9. ncbi Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?
    Charu Aggarwal
    Thoracic Oncology Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Compr Canc Netw 8:822-32. 2010
    ..This article describes these predictive and prognostic markers and details their current role, benefit, and potential future use in the management of patients with NSCLC...
  10. ncbi Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality
    George R Simon
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Int J Biochem Cell Biol 39:1318-28. 2007
    ..This approach is currently being validated in a prospective phase III trial. In the future, assessment of NER function may play a central role in NSCLC treatment decision making...
  11. ncbi Molecular analysis-based treatment strategies for non-small cell lung cancer
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:130-9. 2008
    ..Improved understanding in the molecular biology and genetics of lung cancer has resulted in the identification of individual genes, gene expression profiles, and molecular pathways that may be useful for clinical management decisions...
  12. ncbi Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
    Jade Homsi
    H Lee Moffitt Cancer Center, Tampa, Florida 33612 9497, USA
    Clin Cancer Res 13:5855-61. 2007
    ..We studied a weekly schedule of CT-2106 in patients with refractory solid tumor malignancies...
  13. ncbi Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
    Mayer N Fishman
    Experimental Therapeutics and Phase I Programs, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Clin Cancer Res 12:523-8. 2006
    ..CONCLUSION: The recommended phase II dose for BMS-188797 and carboplatin administered on a once-every-3 week schedule is carboplatin AUC = 5 mg min/mL and BMS-188797 at a dose of 135 mg/m(2)...
  14. ncbi A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
    George R Simon
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    Cancer Chemother Pharmacol 68:1233-41. 2011
    ..This phase I study was carried out to determine the phase II recommended dose of tasisulam sodium (hereafter, tasisulam), a novel anticancer agent with a unique mechanism of action...
  15. ncbi Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung
    Luke T Nordquist
    H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Suite 3170, Tampa, FL 33612, USA
    Chest 126:347-51. 2004
    ....
  16. ncbi Malignant pleural mesothelioma: a comprehensive review
    Roohi Ismail-Khan
    Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:255-63. 2006
    ..In patients with advanced disease, several newer antitumor agents are already showing a capability of extending survival so it is not unreasonable to expect further progress in this area...
  17. ncbi Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines
    Shipra Rastogi
    Drug Discovery Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Lett 257:244-51. 2007
    ..Our results indicate that anti-Glut-1 antibodies inhibit proliferation and induce apoptosis in the evaluated cell lines and provide preliminary evidence of their anti-tumor activity...
  18. ncbi Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, MRC 4W, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    J Clin Oncol 26:3567-72. 2008
    ..This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM...
  19. ncbi Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments
    George R Simon
    Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12002 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Invest 21:87-104. 2003
    ..The article will end with a discussion on newer strategies being currently explored to improve survival in advanced NSCLC...
  20. ncbi Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
    Daanish Hoda
    Division of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Ther Clin Risk Manag 4:1221-7. 2008
    ..This article summarizes the current state-of-the-science knowledge on panitumumab therapy in the treatment of advanced colorectal cancer...
  21. ncbi Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    David J Samson
    Technology Evaluation Center, Blue Cross Blue Shield Association, 1310 G St, NW, Washington, DC 20005, USA
    Chest 132:314S-323S. 2007
    ....
  22. ncbi A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing
    Paula M Fracasso
    The Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 13:986-93. 2007
    ..This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects of cetuximab on patients with epithelial malignancies...
  23. ncbi Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma
    Pasi A Janne
    Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA
    J Clin Oncol 26:1465-71. 2008
    ..Pemetrexed and gemcitabine have single-agent activity in malignant pleural mesothelioma (MPM). The combination of pemetrexed/gemcitabine has not previously been studied in MPM to our knowledge...

Research Grants1

  1. Molecular Analysis-Directed Individualised Therapy in Ad
    George Simon; Fiscal Year: 2005
    ..Patients will be followed till death and survival curves will be generated. ..